Tracking therapeutic progress across multiple phases
| Therapeutic Area / Target / Molecule | Discovery | IND | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
|
Oncology: Pancreatic Cancer, Kidney Cancer Target: TG Alpha Molecule: ADC/ADCGEN04 |
|||||
|
Oncology: T-cell Engager Bi-specific Target: PD1 Molecule: AB-303: bi-specific T-Cell Engaging Antibody |
|||||
|
CNS: NPC1, ALS, HD, PD Target: LLM: Lipid Lysosomal Modulator Molecule: SM/UNDC005 |
|||||
|
CNS: Alzheimer's Disease Target: LLM: Lipid Lysosomal Modulator Molecule: SM/UNDC005 |
|||||
|
Undisclosed - Commercial Asset Target: Undisclosed Molecule: SM |
$$ Pipeline Assets Revenue via Licensing, Commercial Sale of UnDC005
| Therapeutic Area / Target / Molecule | Status | Discovery | IND | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
|
Metabolic/CNS: GLP-1, MASH, NPC1, ALS, HD, PD Modality/ Molecule: SM/UNDC005 Target: LLM: Lipid Lysosomal Modulation |
COMMERCIAL READY
505B/2 ready: For Phase 3.
Licensing/Partnering Discussions
in Parallel
|
Q-1 2026
|
||||
|
Oncology: Pancreatic Cancer, Kidney Cancer Molecule: ADC/ADCGEN04 Target: TG Alpha Partner: Cancer Appy |
Licensing LOI in Place with CB
Therapeutics- Execution in Q2-
2026
|
Q-2, 2026
|
||||
|
Oncology: T-cell Engager Bi-specific Molecule: AB-303: bi-specific Antibody Target: PD1 |
Licensing discussions in progress.
Goal is to out-license. No
|
|||||
|
CNS: Alzheimer's Disease Molecule: ANTIBODY/AB-11 Target: SFRP1 |
Asset Acquisition in progress
|
Q-1 2027
|
||||
|
Oncology: Molecule: AB-10, AB-01: Number of Other Programs |
Collaborations are welcome for the use of Precision.AI in:
DrugTX.AI platform for drug development efforts in:
